Tasty Booshers

[PowerPole]

BIPH--Interview With The CEO:
Biophan CEO Discusses Company's Technology Portfolio and Business Strategy in Interview with WallSt.Net, Available Online
Monday February 14, 6:00 am ET
Company Chief Reports on Progress in Licensing Proprietary Technology for New Generation of Biomedical Products

ROCHESTER, N.Y.--(BUSINESS WIRE)--Feb. 14, 2005-- Biophan Technologies, Inc. (OTCBB: BIPH - News), a developer of next-generation biomedical technology, has announced the availability of an audio interview given by Company CEO, Michael Weiner, to online investor information service WallSt.net.

In the interview, Mr. Weiner described the scope of Biophan's expanding intellectual property portfolio in nanotechnology and other areas that are enabling the development of new biomedical products that can solve critical issues in healthcare. He discussed the Company's product and technology development agreements with leading medical instrument makers such as Boston Scientific, and outlined Biophan's strategy to drive substantial revenue growth through licensing of its proprietary solutions to makers of products for the healthcare and life sciences marketplace.

The ten-minute streaming audio interview can be accessed at http://www.WallSt.net/. To listen, click on the BIPH ticker symbol on the left hand column of the page or enter the BIPH symbol in the Audio Search window. Registration to listen to the interview is free.

Among the specific market sectors areas Mr. Weiner discussed are Biophan's leadership in development of proprietary solutions to allow implanted medical devices, such as pacemakers, to be used safely in Magnetic Resonance Imaging (MRI) environments. The Company has also solved a range of problems that have traditionally prevented other implanted medical devices from being clearly and effectively imaged under MRI.

In addition, Mr. Weiner elaborated on the value of Biophan's planned acquisition of AMRIS, a leading German-based developer of MRI-safe and image-compatible technology solutions and biomedical devices. The planned acquisition will significantly expand Biophan's existing international intellectual property portfolio, granting the Company exclusive license to fifteen issued and pending patents, covering imaging of devices such as stents and other vascular implants. Biophan currently holds a total of 104 U.S. patents, licenses, or applications.
GLTA,